RESUMO

PURPOSE: To analyze the upper eyelid contour after Müller's muscle conjunctiva resection (MMCR) performed by four different surgeons. METHODS: Comparative cross-sectional analysis of the pre- and postoperative contours of a control group and four groups of upper lids (n = 88) of 65 patients who underwent MMCR at four international centers. The procedure employed was essentially the same as described by Putterman but performed with different instruments to entrap the posterior lamella. Multiple medial and lateral margin lid distances were measured on Bézier lines expressing the pre- and postoperative lid contours. RESULTS: Preoperatively, two groups had significant lateral and medial ptosis. After MMCR, the lateral segment of the lid's contour was corrected in all groups. In the two groups with more pronounced ptosis, the nasal lid contour was undercorrected. CONCLUSIONS: In MMCR, regardless of the instrument used to entrap the posterior lamella, the amount of medial tissue resection is essential to avoid postoperative nasal undercorrection. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

RESUMO

PURPOSE: To summarize the development, nomenclature, and rationale of the reported use of monoclonal antibodies (Mabs) in Graves Orbitopathy (GO) and to undertake a systematic review of the management of GO with Mabs. METHODS: The Pubmed and Embase databases and the Federal Brazilian searching site (Periódicos-CAPES) were screened. The authors searched all the keywords "monoclonal antibodies," "adalimumab," "belimumab," "infliximab," "rituximab," "teprotumumab," and "tocilizumab" combined with the terms "Graves Orbitopathy," "Graves eye disease" and "thyroid eye disease." All the articles published in English, French, and Spanish from 2000 to May 2022 were screened. Only publications with quantitative data on the activity of orbitopathy, proptosis, or both were included. RESULTS: Seventy-six articles of the 954 screened records met the inclusion criteria. Seven Mabs were described for treating GO. The three most reported Mabs were Rituximab, Tocilizumab, and Teprotumumab. Only eight randomized clinical trials compared the effect of these three Mabs and Belimumab with the effect of steroids or placebos. Adalimumab, Infliximab, and K1-70 only appeared in a few case series and case reports. Frequent mild-to-moderate and few major side effects occurred with the three most used Mabs. Relapse rates ranged from 7.4% for Tocilizumab to at least 29.4% for Teprotumumab. No randomized clinical trials compared Mabs head-to-head. CONCLUSION: Considering the lack of head-to-head comparisons between Mabs, the relapse rate, the possibility of severe collateral effects, and the cost of Mabs, it is not clear which Mab is the safest and most useful to treat GO.

Assuntos

RESUMO

At cell surface gangliosides might associate with signal transducers proteins, grown factor receptors, integrins, small G-proteins and tetraspanins establishing microdomains, which play important role in cell adhesion, cell activation, motility, and growth. Previously, we reported that GM2 and GM3 form a heterodimer that interacts with the tetraspanin CD82, controlling epithelial cell mobility by inhibiting integrin-hepatocyte growth factor-induced cMet tyrosine kinase signaling. By using molecular dynamics simulations to study the molecular basis of GM2/GM3 interaction we demonstrate, here, that intracellular levels of Ca2+ mediate GM2/GM3 complexation via electrostatic interaction with their carboxyl groups, while hydrogen bonds between the ceramide groups likely aid stabilizing the complex. The presence of GM2/GM3 complex alters localization of CD82 on cell surface and therefore downstream signalization. These data contribute for the knowledge of how glycosylation may control signal transduction and phenotypic changes.

Assuntos

RESUMO

OBJETIVO: Avaliar a correlação da fluência e o tempo de parada transoperatória por perda de fixação, como fatores de hiper ou hipocorreções das ametropias pós-Lasik. MÉTODOS: A idade variou entre 19 e 61 anos com média de 31,27 ± 9,99. O tempo mínimo de acompanhamento pós-operatório foi de 90 dias. Foram excluídos indivíduos com topografia corneana pré-operatória com ceratometria máxima maior que 46,5D ou presença de irregularidades; ceratometria média pós-operatória simulada menor que 36,0D; pupilas maiores que 6mm; paquimetria menor que 500 µm; miopia maior que -8,0DE, hipermetropia maior que +5,0DE e astigmatismo maior que -4,0DC. O laser utilizado foi o Esiris Schwind com Eye-Tracking de 350Hz e scanning spot de 0,8 mm. O microcerátomo utilizado foi o M2 da Moria com programação de 130µm de espessura. RESULTADOS: A acuidade visual logMAR pré-operatória com correção variou de 0,40 a 0 com média de 0,23 ± 0,69; a pós-operatória sem correção foi de 0,40 a 0 com média de 0,30 ± 0,68. A mediana foi de 0 logMAR para os dois momentos (p=0,424). No equivalente esférico pré e pós-operatório, notou-se uma óbvia diferença (p< 0,0001), no pré-operatório com média de -4,09 ± 2,83 e o pós com média de -0,04 ± 0,38. A mediana foi de -4,75 no pré e de 0 no pós-operatório. Sessenta e nove casos (78,3%) ficaram plano ± 0,25. A fluência mínima foi de 0,513 mJ/cm² e a máxima de 0,581 mJ/cm² com média de 0,545 ± 0,01, não se percebendo correlação (r= -0,03266; IC 95% -0,241 a 0,178; p= 0,762) entre a fluência e o equivalente esférico final (média= -0,04 ± 0,38) nos olhos operados. O tempo mínimo de parada transoperatória foi de dois segundos e o máximo de 12 segundos com média de 4,90 ± 3,47. Fazendo-se uma correlação (r= 0,08865; IC 95%= -0,123 a 0,293; p= 0,411) entre o equivalente esférico pós-operatório e o tempo de parada transoperatória, não se percebeu diferenças. CONCLUSÃO: Não houve correlação entre a fluência do laser e o tempo de parada transoperatória por perda de fixação, com hiper ou hipocorreções nas ametropias pós-Lasik.

OBJECTIVE: To evaluate the correlation of flow and stopping time intraoperative loss of attachment factors as hypertension or hipocorreções of refractive errors after Lasik. METHODS: The age ranged between 19 and 61 years (mean= 31.27 ± 9.99). The minimum follow-up period was 90 days. Individuals with: corneal topography preoperative maximum keratometry greater than 46.5D or presence of irregularities, corneal curvature postoperative simulated smaller 36.0D, pupils more 6mm; corneal thickness smaller 500 µm; Myopia more -8.0, hyperopia more +5.0DE and astigmatism more -4.0DC. The laser was used with Esir Schwind Eye-Tracking and 350Hz scanning spot of 0.8 mm. The microkeratome used was the Moria M2 with programming 130µm thick. RESULTS: The visual acuity logMAR preoperative correction ranged from 0.40 to 0 (mean= 0.23 ± 0.69) and postoperative uncorrected 0.40-0 (x= 0.30 ± 0, 68). The Median= 0 logMAR for both time points (p= 0.424). For spherical equivalent before and after surgery, we found an obvious difference, with the pre (mean= -4.09 ± 2.83) and post (mean= -0.04 ± 0.38). The Median was -4.75 in the pre and zero postoperatively (p <0.0001). Sixty-nine cases (78.3%) were plan ± 0.25. Fluency minimum= 0.513 mJ/cm2 and maximum= 0.581 mJ/cm2 (mean= 0.545 ± 0.01), no correlation (r = -0.03266, 95% CI -0.241 to 0.178, p = 0.762) between the flow and spherical equivalent (mean = -0.04 ± 0.38) in eyes operated. The minimal downtime during surgery was 02 seconds and maximum was 12 seconds (mean= 4.90 ± 3.47). Making a correlation (r = 0.08865, 95% CI = -0.123 to 0.293, p = 0.411) between the postoperative spherical equivalent and downtime during surgery, not perceived differences. CONCLUSION: There was no correlation between the fluency of the laser during surgery and downtime due to loss of fixation with hipocorreções in hyper-or post-Lasik ametropia.

Assuntos